The global cloning and mutagenesis market size was USD 3.53 billion in 2023, estimated at USD 4.21 billion in 2024 and is anticipated to reach around USD 22.27 billion by 2034, expanding at a CAGR of 18.12% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cloning and Mutagenesis Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cloning and Mutagenesis Market, by Product, 2024-2034
8.1.1 Cloning Kits
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Mutagenesis Kits
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. Cloning and Mutagenesis Market, by Technology, 2024-2034
9.1.1. Topo PCR Cloning
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Blunt End Cloning
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Seamless Cloning
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Site-directed Mutagenesis
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2034)
10.1. Cloning and Mutagenesis Market, by End-User, 2024-2034
10.1.1. Biopharmaceutical & Pharmaceutical Companies
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. CROs & CMOs
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Academic & Research Institutes
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2021-2034)
11.1.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.3. Market Revenue and Forecast, by End-User (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End-User (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End-User (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End-User (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End-User (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.3. Market Revenue and Forecast, by End-User (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End-User (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End-User (2021-2034)
12.1. Thermo Fisher Scientific, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Agilent Technologies, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. New England Biolabs
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Merck KGaA
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Takara Bio Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Promega Corporation
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Bio-Rad Laboratories, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Jena Bioscience GmbH
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Danaher
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Assay Genie
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample